Dive into the evolving world of Hodgkin Lymphoma (HL)—a once-feared cancer now boasting cure rates over 90%. In this episode, we:
- Explore cellular roots with Reed–Sternberg “owl‑eye” cells and how HL evades the immune system
- Explain definitive diagnosis via lymph node biopsy and PET-based staging
- Detail modern, risk-adapted treatments: refined chemo regimens (ABVD, OEPA), targeted therapy like brentuximab vedotin, and checkpoint inhibitors nivolumab & pembrolizumab
- Highlight strategies to reduce long-term harm: response-adapted therapy, minimizing or avoiding radiation
- Look at relapse plans including salvage chemo & autologous stem cell transplant, plus novel options like CAR‑T and antibody–drug conjugates
- Stress survivorship essentials: lifelong monitoring for second cancers (breast, lung), heart & thyroid health, fertility, and mental wellbeing
- Discuss cutting-edge research areas: liquid biopsies (ctDNA) and personalized care based on tumor biology
Whether you’re newly diagnosed, in treatment, or a survivor seeking insight, this episode gives clear, essential perspectives.
